-
Kuros Biosciences to present at upcoming clinical and investor conferences
Kuros Biosciences (SIX: KURN), a leader in next generation bone graft technologies and a pioneer in the emerging field of osteoimmunology, today announced that the company will present at two major European conferences in March, both to be held virtually. Joost de Bruijn, Chief Executive Officer, and Michael Grau, Chief Financial Officer, will participate in the 18th edition of BioCapital Europe, the premier life investment venue organized by LSP on March 11. Joost de Bruijn will deliver a corporate presentation at 11.30 CET, and be available, with Michael Grau, for 1×1 meetings with investors. For more info about this event, please visit the meeting website: https://www.biocapitaleurope.com Kuros will also present…
-
Kuros Biosciences announces MagnetOs sales and distribution agreements across Northern Europe
Agreements in Netherlands, Switzerland and Austria and letter of intent in Finland Supports further acceleration of sales of MagnetOs bone graft Kuros Biosciences (SIX: KURN) today announced that it has signed sales and distribution agreements for MagnetOs bone graft, covering the Netherlands, Switzerland, Austria, and Finland. These add to an existing agreement in the United Kingdom and Ireland. Kuros has signed a sales agency agreement with Lubbers Medical BV giving Lubbers non-exclusive rights to sell MagnetOs in the Netherlands, effective Q4 2020. Kuros has signed exclusive stocking distributor agreements for Switzerland and Austria with Orthocontor AG and Amacord GmbH, respectively, both effective Q1 2021. Kuros and Arthrone Oy have signed…
-
Kuros Biosciences wins 2020 Spine Technology Award from Orthopedics This Week
. Industry-leading award recognizes Kuros’ Fibrin-PTH (KUR-113) technology Rounds off successful year of commercial, clinical, and financial progress Kuros also wins GHP Magazine’s 2020 International Life Science Award Kuros Biosciences (SIX: KURN) today announced that it has won the 2020 Spine Technology Award, awarded by the widely-read industry publication Orthopedics This Week for outstanding innovations in the field, for its Fibrin-PTH (KUR-113) technology, which delivers targeted and controlled bone formation. The prestigious award rounds off a year of strong progress for Kuros. Sales of lead product MagnetOs are accelerating, and the company has successfully initiated the STRUCTURE Phase 2 study with Fibrin-PTH, the first investigational trial of a drug…
-
Kuros announces results of Rights Offering
Kuros Biosciences (SIX: KURN) (the Company or Kuros) announces the results of its Rights Offering, first announced on October 5, 2020, in which a total of up to 8,426,229 newly registered shares of Kuros with a nominal value of CHF 1.00 each were offered to Kuros’ existing shareholders at an Offer Price of CHF 1.80 per share. At expiration of the rights exercise period on October 19, 2020, 12.00 noon CEST, subscription rights for 4,233,699 newly registered shares were validly exercised, representing 50.2% of the newly registered shares offered. 4,192,530 newly registered shares for which subscription rights were not validly exercised will be offered in the Share Placement to eligible…
-
Kuros Biosciences to present new data on the role of osteoimmunology in bone formation at NASS 2020 Annual Meeting
Kuros Biosciences today announced it will unveil new research on the role of osteoimmunology in bone formation in three presentations at the North American Spine Society (NASS) 2020 Annual Meeting, held virtually, October 6-9. Kuros is a leader in next generation bone graft technologies and a pioneer in this emerging field of osteoimmunology. Research to be presented at the NASS meeting demonstrates the following properties following treatment with Kuros’ MagnetOs: Direct upregulation of pro-healing, anti-inflammatory immune cells by the unique needle-shaped surface of Kuros’ MagnetOsTMadvanced bone graft. Increased vascularization by epithelial cells grown in the same pro-healing microenvironment compared to the market-leading synthetic bone graft, Vitoss®. Cells of the immune system…
-
Kuros Biosciences reports MagnetOs products approved in Australia
MagnetOs Granules and MagnetOs Putty receive TGA approval in Australia Initial launch of MagnetOs on the Australian market scheduled for late Q1 2021. Kuros Biosciences BV, the Dutch subsidiary of Kuros Biosciences AG (SIX: KURN), today announced that MagnetOs Granules and MagnetOs Putty have both been entered on the Australian Register of Therapeutic Goods allowing marketing and sales on the Australian market. Surgical Specialties Pty Ltd, Kuros’s Australian distributor, intends to start marketing MagnetOs as soon as it is listed on The Prostheses List, anticipated on March 1, 2021. The Prostheses List identifies the medical devices, including surgically implanted prostheses and human tissue items, that are eligible for reimbursement from…
-
Kuros Biosciences Hosts an Expert Perspectives Webinar on Pioneering Solutions for Targeted and Controlled Bone Healing
Kuros Biosciences (SIX: KURN), a leader in next generation bone graft technologies, will host an expert perspectives webinar on pioneering solutions for targeted and controlled bone healing on Wednesday, October 14, 2020 at 2pm Central European Time (CET). The call will feature a presentation by Key Opinion Leaders John Chi, MD, MPH, Brigham and Women’s Hospital, and Alpesh Patel, MD, Northwestern Medicine, who will discuss Kuros’s products, Fibrin-PTH (KUR-113) and MagnetOs, which promote targeted and controlled bone healing. Drs. Patel and Chi will be available to answer questions at the conclusion of the call. Joost de Bruijn, Kuros’s CEO, will also give a brief corporate update. This KOL event is…
-
Kuros reaches milestone of 2,000 patients treated with MagnetOs bone graft
Strong adoption by spinal surgeons since U.S. launch in September 2019 Sales accelerating with over 2,000 patients treated to date Kuros Biosciences (SIX: KURN) today announced that over 2,000 patients have been treated worldwide with its MagnetOs bone graft, an alternative to the gold standard treatment of autograft. A substantial, and growing, number of clinically relevant and predictive animal studies have demonstrated the equivalence of MagnetOs to the current gold standard of autograft and MagnetOs is now supported by over three years of clinical experience since its launch in the UK in May 2017. Sales are on track and accelerating. MagnetOs bone graft has an advanced submicron surface topography that…
-
Kuros Convenes Extraordinary General Meeting
Kuros Biosciences (SIX: KURN) today announced that it will hold an Extraordinary General Meeting (EGM) of shareholders to seek approval to increase the Company’s ordinary share capital. The EGM will be held at Kuros Biosciences AG, Wagistrasse 25, 8952 Schlieren, Switzerland on 5 October 2020 at 11am CEST. The share capital increase aims at raising up to around CHF 15 million by issuing up to 9 million newly created ordinary shares. The Company intends to use the net proceeds to accelerate and advance the commercial roll-out of MagnetOs, which based on current performance is expected to become cash flow positive for the Company by the end of 2022. The proceeds…
-
Kuros Biosciences Announces Treatment of the First Patient in its Spinal Fusion Trial with Fibrin-PTH
First investigational trial of a drug-biologic bone graft for spine fusion Phase 2 trial in the U.S. compares Fibrin-PTH (KUR-113) with local autograft Primary endpoint is radiographic interbody fusion at 12 months Potential to address a major commercial opportunity Kuros Biosciences, a leader in next generation bone graft technologies, today announced that the first patient has been treated in the STRUCTURE trial, investigating Fibrin-PTH (KUR-113) for transforaminal lumbar interbody fusion (TLIF) procedures in patients with degenerative disc disease. The first patient was treated by Dr Richard Todd Allen, principal investigator at University California San Diego. The STRUCTURE trial is conducted under an open Investigational New Drug (IND) for spinal fusion, which…
